`

John Lechleiter

Lechleiter: After the deluge, we'll be fine

Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.
Read More

UPDATE: Pipeline challenges force Lilly restructuring moves

Since John Lechleiter was named CEO 18 months ago, he's bet that Eli Lilly and Co. could face down its looming patent challenges by launching innovative new medicines. Today's announcement of 5,500 job cuts by the end of 2011 and a restructuring of the company's business units ups the ante on that bet, while indicating that it isn't working yet.
Read More

With pharma famine looming, Lilly relying on snack-size deals

Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year, Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
Read More

New Lilly CEO called analytical, 'incredibly warm'

John C. Lechleiter, whom Eli Lilly and Co.'s board voted to replace Sidney Taurel as CEO, is known for getting things done and yet also for being good at analysis and relating to people under him. Taurel will step down at the end of March but remain chairman until the end of 2008.
Read More